ClinicalTrials.gg
RecruitingNCT07611747PREVENERUpdated Nov 19, 2026

Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)

A Phase 4 interventional study of Carotid Ultrasound and High-intensity lipid-lowering therapy in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Systemic Lupus Erythematosus (SLE), sponsored by Instituto de Investigación Marqués de Valdecilla. Recruiting at 17 sites in Spain. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Instituto de Investigación Marqués de Valdecilla · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 19, 2026Site recruiting status changedEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,117
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 265 studies in Arthritis, Rheumatoid with a site in Spain — 20 open to participants now, 35 under way, 3 of them phase 3. Arthritis, Rheumatoid · Spain.

Planned enrollment
28th of 220
1,117 · median 299
Started
2026
with 5 others
Phase 4
22 of 265
1 open now
Primary completion
2031-04
later than 32 of 34 live
Registered
262nd of 265
by date

Among the 265 studies in Arthritis, Rheumatoid with a site in Spain, this one is the 28th largest by planned enrollment of the 220 interventional ones that give a count, is one of 6 that started in 2026, is one of 22 in phase 4, reaches primary completion later than 32 of the 34 other live ones, and was the 262nd registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

20 of the 265 studies in Arthritis, Rheumatoid with a site in Spain are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Arthritis, Rheumatoid with a site in Spain, or all of them as a file.
02

Study summary

PREVENER is a randomized, open-label, multicenter, phase IV clinical trial designed to evaluate the efficacy and safety of a carotid ultrasound-based strategy for the primary prevention of cardiovascular events in patients with inflammatory rheumatic diseases (IRD).

Patients with IRD, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (AxSpA), and systemic lupus erythematosus (SLE), have a 50% higher risk of cardiovascular (CV) events compared to the general population. However, conventional CV risk scores (SCORE2/OP) systematically underestimate this risk, leaving many high-risk patients without appropriate preventive treatment.

Patients aged ≥50 years with IRD and low-to-moderate CV risk according to SCORE2/OP will be randomized 1:1 to either an experimental group (carotid ultrasound to detect subclinical atherosclerosis) or a control group (standard care according to ESC 2021 guidelines). Patients in the experimental group with carotid plaques will be reclassified as very high CV risk and treated with high-intensity statins (LDL target \<55 mg/dL). The primary endpoint is the incidence of major adverse cardiovascular events (MACE) over 48 months of follow-up.

Read the detailed description

Background:

Patients with chronic inflammatory rheumatic diseases (RA, PsA, AxSpA, SLE) carry a significantly increased risk of atherosclerotic cardiovascular events compared to the general population. This excess risk is largely attributed to the pro-atherogenic effect of chronic inflammation. Despite this, conventional CV risk stratification tools such as SCORE2/OP do not account for inflammation-related risk, leading to systematic underestimation of CV risk in these patients. Data from the CARMA project demonstrated that 53% of CV events in Spanish patients with IRD occurred in those classified as low-to-moderate risk by SCORE2/OP, highlighting the urgent need for improved risk stratification strategies.

Carotid ultrasound for the detection of subclinical atherosclerosis (carotid plaques) has been proposed as a modifier of CV risk in the ESC 2021 guidelines. The presence of carotid plaques automatically reclassifies individuals to very high CV risk, warranting intensive lipid-lowering therapy. However, no randomized clinical trial has evaluated the efficacy of this strategy in patients with IRD.

Study Design:

PREVENER is an open-label, randomized, multicenter, phase IV clinical trial. Patients aged ≥50 years with IRD (RA by ACR/EULAR 2010 criteria, PsA by CASPAR criteria, AxSpA by ASAS criteria, or SLE by ACR/EULAR 2019 criteria) and low-to-moderate CV risk according to SCORE2/OP will be enrolled across 17 Spanish hospitals.

Eligible patients will be randomized 1:1 to:

  • Experimental group: carotid ultrasound performed within 30 days of randomization. Patients with carotid plaques (defined by Mannheim consensus criteria) will be classified as very high CV risk and initiated on high-intensity statin therapy (LDL target \<55 mg/dL). Patients without plaques will be managed according to ESC 2021 guidelines.
  • Control group: standard management according to ESC 2021 guidelines throughout the study.

Randomization will be performed using REDCap, stratified by age, sex, classic CV risk factors, lipid-lowering treatment, rheumatic disease, and advanced therapy use.

Primary Endpoint:

Incidence of major adverse cardiovascular events (MACE), defined as: acute myocardial infarction or stroke, hospitalization for unstable angina, arterial revascularization for peripheral arterial disease, or CV death.

Secondary Endpoints:

  1. Efficacy of the strategy analyzed individually by rheumatic disease (RA, PsA, AxSpA)
  2. Comparison of efficacy between men and women
  3. Safety comparison of adverse events between groups

Follow-up:

All patients will be followed for 48 months. Patients on lipid-lowering treatment will have monthly visits during the intensification phase (maximum 5 visits) until therapeutic target is achieved, followed by semi-annual visits until month 48. Patients not requiring lipid-lowering treatment will have semi-annual visits throughout.

Statistical Analysis:

The primary analysis will follow an intention-to-treat approach. Cox regression models will be used to calculate Hazard Ratios with 95% confidence intervals, adjusted for relevant covariates. Kaplan-Meier survival curves will be compared using the log-rank test. Based on a 4-year incidence of first CV event of 3.2% in patients aged ≥50 years with IRD and low-to-moderate SCORE2/OP risk (CARMA project), and assuming a 50% reduction in events among experimental-group patients with carotid plaques (estimated to account for 85% of events in that group), the expected incidence in the experimental group is 1.91%. With 80% power and a two-sided alpha of 0.05, 1,064 patients are required (1,117 allowing for \<5% loss to follow-up). An interim analysis will be performed at 50% of expected events using the O'Brien-Fleming stopping rule, reviewed by an independent Data Safety Monitoring Board (DSMB).

03

Conditions studied

  • Rheumatoid Arthritis (RA)
  • Psoriatic Arthritis (PsA)
  • Systemic Lupus Erythematosus (SLE)
  • Carotid Artery Diseases
  • Cardio Vascular Disease
  • Atheroscleroses
  • Axial Spondyloarthritis

Keywords

  • Carotid ultrasound
  • Carotid plaques
  • Subclinical atherosclerosis
  • Cardiovascular prevention
  • Inflammatory rheumatic diseases
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥50 years who have provided written .
  2. Fulfillment of classification criteria for at least one of the following inflammatory rheumatic diseases:

    • Rheumatoid arthritis (RA) according to ACR/EULAR 2010 criteria
    • Psoriatic arthritis (PsA) according to CASPAR criteria
    • Axial spondyloarthritis (AxSpA) according to ASAS criteria
    • Systemic lupus erythematosus (SLE) according to ACR/EULAR 2019 criteria
  3. Low-to-moderate cardiovascular risk according to SCORE2/OP classification.

Exclusion criteria

Exclusion Criteria:

  1. Presence of previous cardiovascular events, type 2 diabetes mellitus, familial hypercholesterolemia, or chronic kidney disease resulting in classification as high or very high cardiovascular risk.
  2. Prior carotid ultrasound examination with subsequent therapeutic intervention derived from its results, either in the context of a research study or routine clinical practice.
  3. to lipid-lowering therapy, including recent history of alcoholism, active liver disease, or unexplained and persistent elevation of serum transaminases exceeding three times the (applicable to statins and ezetimibe).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,117 participants (estimated)

Study arms

  • Experimental
    Experimental Group: Carotid Ultrasound

    Patients undergo carotid ultrasound within 30 days of randomization. Patients with carotid plaques are reclassified as very high cardiovascular risk and initiated on high-intensity statin therapy (LDL target \< 55 mg/dL). Patients without carotid plaques are managed according to ESC 2021 guidelines.

    Diagnostic Test: Carotid Ultrasound · Drug: High-intensity lipid-lowering therapy

  • Active comparator
    Control Group: Standard Care

    Patients are managed according to standard ESC 2021 cardiovascular prevention guidelines throughout the study, without carotid ultrasound assessment.

    Other: Standard care according to ESC 2021 guidelines

Interventions

  • Diagnostic testCarotid Ultrasound

    Carotid ultrasound performed to detect subclinical atherosclerosis (carotid plaques) according to Mannheim consensus criteria. The presence of carotid plaques triggers reclassification to very high cardiovascular risk and initiation of high-intensity lipid-lowering therapy.

  • DrugHigh-intensity lipid-lowering therapy

    Sequential lipid-lowering therapy initiated in experimental group patients with carotid plaques, targeting LDL \< 55 mg/dL. Treatment includes high-intensity statins (atorvastatin 40-80mg, rosuvastatin 20-40mg), with possible addition of ezetimibe, bempedoic acid, and/or PCSK9 inhibitors if target is not achieved.

  • OtherStandard care according to ESC 2021 guidelines

    Lipid-lowering treatment indicated and managed according to ESC 2021 cardiovascular prevention guidelines, based on SCORE2/OP risk stratification, without carotid ultrasound assessment.

06

What researchers measure

Primary outcomes

  1. Incidence of Major Adverse Cardiovascular Events (MACE)

    Composite of acute myocardial infarction, stroke, hospitalization for unstable angina, arterial revascularization for peripheral arterial disease, or cardiovascular death, whichever occurs first.

    Time frame: 48 months

Secondary outcomes

  1. Number of Participants Experiencing an Acute Myocardial Infarction or Stroke

    Incidence of acute myocardial infarction or stroke during the follow-up period.

    Time frame: 48 months

  2. Number of Participants Hospitalized for Unstable Angina

    Incidence of hospital admissions due to unstable angina during the follow-up period.

    Time frame: 48 months

  3. Number of Participants Requiring Arterial Revascularization for Peripheral Arterial Disease

    Incidence of arterial revascularization procedures required for peripheral arterial disease during the follow-up period.

    Time frame: 48 months

  4. Number of Participants Experiencing Cardiovascular Death

    Incidence of cardiovascular death during the follow-up period.

    Time frame: 48 months

  5. Number of Participants Experiencing a Major Cardiovascular Event. Stratified by Rheumatic Disease Subgroup

    Evaluation of the incidence of major cardiovascular events (acute myocardial infarction, stroke, hospitalization for unstable angina, arterial revascularization for peripheral artery disease, or cardiovascular death) analyzed individually for each included inflammatory disease (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and systemic lupus erythematosus).

    Time frame: 48 months

  6. Number of Participants Experiencing a Major Cardiovascular Event. Analyzed by Sex

    This measure evaluates the efficacy of the strategy by comparing the incidence of individual cardiovascular events (acute myocardial infarction, stroke, hospitalization for unstable angina, arterial revascularization or cardiovascular death) between male and female participants.

    Time frame: 48 months

  7. Incidence of adverse events

    Time frame: 48 months

  8. LDL cholesterol levels

    Time frame: 48 months

07

Study locations

16 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2031, 60 months after the start.

Of 79 non-industry phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 92. This study's planned 60 months is above that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2026
First posted
May 28, 2026
StartActual
Apr 22, 2026
Primary completionEst.
Apr 22, 2031
CompletionEst.
Dec 2031
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed. 8 sites changed recruiting status (8 now recruiting)
Show 8 sites
  • Hospital Universitario de Elche · Elche, SpainNot yet recruiting→Recruiting
  • Hospital Universitario Marqués de Valdecilla · Santander, SpainNot yet recruiting→Recruiting
  • Hospital General Universitario de Ciudad Real · Ciudad Real, SpainNot yet recruiting→Recruiting
  • Hospital Universitario Reina Sofía · Córdoba, SpainNot yet recruiting→Recruiting
  • Hospital Universitari Son LLàtzer · Palma, SpainNot yet recruiting→Recruiting
  • Hospital Universitario La Paz · Madrid, SpainNot yet recruiting→Recruiting
  • Hospital Universitario Ramón y Cajal · Madrid, SpainNot yet recruiting→Recruiting
  • Hospital Universitario de Canarias · San Cristóbal de La Laguna, SpainNot yet recruiting→Recruiting
Show 2 added (2 Spain)
  • Hospital Universitario San Juan de Alicante · Sant Joan d'Alacant, Spain
  • Hospital Universitario Virgen de la Arrixaca · Murcia, Spain
Show 2 removed
  • Hospital General Universitario de Alicante · Alicante, Spain
  • Hispital Universitario Virgen de la Arrixaca · Murcia, Spain
Nov 19, 2026
Enrollment
1944→1117
Nov 19, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionIncidence of Major Adverse Cardiovascular Events (MACE): how it is measured was reworded
Nov 19, 2026
Show all 2 updates
  1. Nov 19, 2026
    2 sites added, 2 sites removed. 8 sites changed recruiting status (8 now recruiting)
    Show 8 sites
    • Hospital Universitario de Elche · Elche, SpainNot yet recruiting→Recruiting
    • Hospital Universitario Marqués de Valdecilla · Santander, SpainNot yet recruiting→Recruiting
    • Hospital General Universitario de Ciudad Real · Ciudad Real, SpainNot yet recruiting→Recruiting
    • Hospital Universitario Reina Sofía · Córdoba, SpainNot yet recruiting→Recruiting
    • Hospital Universitari Son LLàtzer · Palma, SpainNot yet recruiting→Recruiting
    • Hospital Universitario La Paz · Madrid, SpainNot yet recruiting→Recruiting
    • Hospital Universitario Ramón y Cajal · Madrid, SpainNot yet recruiting→Recruiting
    • Hospital Universitario de Canarias · San Cristóbal de La Laguna, SpainNot yet recruiting→Recruiting
    Show 2 added (2 Spain)
    • Hospital Universitario San Juan de Alicante · Sant Joan d'Alacant, Spain
    • Hospital Universitario Virgen de la Arrixaca · Murcia, Spain
    Show 2 removed
    • Hospital General Universitario de Alicante · Alicante, Spain
    • Hispital Universitario Virgen de la Arrixaca · Murcia, Spain
    Enrollment 1944→1117
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionIncidence of Major Adverse Cardiovascular Events (MACE): how it is measured was reworded
    + 4 other changes: identifiers, verification date, description and arm descriptions
  2. Nov 10, 2026
    Minor edits only
    + 3 other changes: index terms, identifiers and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07611747
Lead sponsor
Instituto de Investigación Marqués de Valdecilla
Responsible party
Sponsor
First posted
May 28, 2026
Start date
Apr 22, 2026
Primary completion
Apr 22, 2031 (estimated)
Completion
Dec 2031 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion